These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
317 related items for PubMed ID: 31060488
1. Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text. Kolovou GD, Watts GF, Mikhailidis DP, Pérez-Martínez P, Mora S, Bilianou H, Panotopoulos G, Katsiki N, Ooi TC, Lopez-Miranda J, Tybjærg-Hansen A, Tentolouris N, Nordestgaard BG. Curr Vasc Pharmacol; 2019; 17(5):498-514. PubMed ID: 31060488 [Abstract] [Full Text] [Related]
2. Postprandial Hypertriglyceridaemia Revisited in the Era of Non-fasting Lipid Profiles: Executive Summary of a 2019 Expert Panel Statement. Kolovou GD, Watts GF, Mikhailidis DP, Pérez-Martínez P, Mora S, Bilianou H, Panotopoulos G, Katsiki N, Ooi TC, Lopez-Miranda J, Tybjærg-Hansen A, Tentolouris N, Nordestgaard BG. Curr Vasc Pharmacol; 2019; 17(5):538-540. PubMed ID: 31418346 [No Abstract] [Full Text] [Related]
3. Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Narrative Review. Kolovou GD, Watts GF, Mikhailidis DP, Pérez-Martínez P, Mora S, Bilianou H, Panotopoulos G, Katsiki N, Ooi TC, Lopez-Miranda J, Tybjærg-Hansen A, Tentolouris N, Nordestgaard BG. Curr Vasc Pharmacol; 2019; 17(5):515-537. PubMed ID: 31309820 [Abstract] [Full Text] [Related]
4. Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Kolovou GD, Mikhailidis DP, Kovar J, Lairon D, Nordestgaard BG, Ooi TC, Perez-Martinez P, Bilianou H, Anagnostopoulou K, Panotopoulos G. Curr Vasc Pharmacol; 2011 May; 9(3):258-70. PubMed ID: 21314632 [Abstract] [Full Text] [Related]
5. Assessment of postprandial triglycerides in clinical practice: Validation in a general population and coronary heart disease patients. Perez-Martinez P, Alcala-Diaz JF, Kabagambe EK, Garcia-Rios A, Tsai MY, Delgado-Lista J, Kolovou G, Straka RJ, Gomez-Delgado F, Hopkins PN, Marin C, Borecki I, Yubero-Serrano EM, Hixson JE, Camargo A, Province MA, Lopez-Moreno J, Rodriguez-Cantalejo F, Tinahones FJ, Mikhailidis DP, Perez-Jimenez F, Arnett DK, Ordovas JM, Lopez-Miranda J. J Clin Lipidol; 2016 May; 10(5):1163-71. PubMed ID: 27678433 [Abstract] [Full Text] [Related]
6. Nonfasting versus fasting lipid profile for cardiovascular risk prediction. Langsted A, Nordestgaard BG. Pathology; 2019 Feb; 51(2):131-141. PubMed ID: 30522787 [Abstract] [Full Text] [Related]
7. Who would benefit most from postprandial lipid screening? Sciarrillo CM, Koemel NA, Keirns BH, Banks NF, Rogers EM, Rosenkranz SK, Kurti SP, Jenkins NDM, Emerson SR. Clin Nutr; 2021 Jul; 40(7):4762-4771. PubMed ID: 34242916 [Abstract] [Full Text] [Related]
8. Postprandial lipaemia in menopausal women with metabolic syndrome. Kolovou GD, Anagnostopoulou KK, Pavlidis AN, Salpea KD, Hoursalas IS, Manolis A, Cokkinos DV. Maturitas; 2006 Aug 20; 55(1):19-26. PubMed ID: 16443339 [Abstract] [Full Text] [Related]
9. Clinical relevance of non-fasting and postprandial hypertriglyceridemia and remnant cholesterol. Nordestgaard BG, Freiberg JJ. Curr Vasc Pharmacol; 2011 May 20; 9(3):281-6. PubMed ID: 21314630 [Abstract] [Full Text] [Related]
10. HDL-associated apoCIII plays an independent role in predicting postprandial hypertriglyceridemia. Zhang T, Tang X, Mao L, Chen J, Kuang J, Guo X, Xu D, Peng D, Yu B. Clin Biochem; 2020 May 20; 79():14-22. PubMed ID: 32045574 [Abstract] [Full Text] [Related]
14. Exacerbation of insulin resistance and postprandial triglyceride response in newly diagnosed hypertensive patients with hypertriglyceridaemia. Hwu CM, Kwok CF, Kuo CS, Hsiao LC, Lee YS, Wei MJ, Kao WY, Lee SH, Ho LT. J Hum Hypertens; 2002 Jul 19; 16(7):487-93. PubMed ID: 12080433 [Abstract] [Full Text] [Related]
20. Fasting Is Not Routinely Required for Determination of a Lipid Profile: Clinical and Laboratory Implications Including Flagging at Desirable Concentration Cutpoints-A Joint Consensus Statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Nordestgaard BG, Langsted A, Mora S, Kolovou G, Baum H, Bruckert E, Watts GF, Sypniewska G, Wiklund O, Borén J, Chapman MJ, Cobbaert C, Descamps OS, von Eckardstein A, Kamstrup PR, Pulkki K, Kronenberg F, Remaley AT, Rifai N, Ros E, Langlois M, European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Joint Consensus Initiative. Clin Chem; 2016 Jul 19; 62(7):930-46. PubMed ID: 27235445 [Abstract] [Full Text] [Related] Page: [Next] [New Search]